Evaluation of community pharmacist ability to ensure the safe use of oral anticancer agents: a nationwide survey in Japan

Suzuki, Shinya; Abbott, Rick; Sakurai, Hiroomi; Kawasumi, Kenji; Johnson, Philip E.; Tahara, Makoto; Yamaguchi, Masakazu; Saito, Shinichiro; Yee, Gary C.; Endo, Kazushi

doi:10.1093/jjco/hyx015

Cited by 25 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite several limitations, our findings are consistent with previous pharmacist surveys of dispensing practices and educational needs, 13,17 and with what we expected in terms of current practice, oncology training, and CE needs around toxicity management. The results of this study suggest that a multi-pronged approach that addressed education/training (undergraduate and continuous professional development) and improving communication with cancer providers may positively influence toxicity management by community pharmacists.…”

Section: Resultssupporting

confidence: 90%

“…Attending a CE event related to toxicity management in the past 12 months was positively correlated with encounters with treatment-related toxicities and communicating with the oncology team at the cancer centre, suggesting that education and training may influence practice, a finding described in previous studies. 5,13,17 Despite 37% of pharmacists indicating that they routinely provide advice to patients on toxicity management, they are less likely to assess and monitor patients, unless requested to do so. These results are not surprising as counselling and providing advice when requested is part of the current Canadian standards of practice.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…5 More recently, a similar Japanese survey found that only 6–10% of community pharmacists felt that they had received adequate oncology education and 40% felt comfortable educating patients about oral chemotherapy. 13 While previous studies focused on community pharmacists’ dispensing practices and educational needs around OACD in general, our study focuses on gaining a better understanding of the behaviours and preferences of community pharmacists specific to the management of treatment-related toxicities. We wanted to understand Ontario community pharmacists’ current practice of toxicity management, including determining their educational needs and communication practices with cancer centres.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Managing chemotherapy-related toxicities in the community setting: A survey of pharmacists in Ontario

Pardhan

Lakhani

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background: Toxicity management is a challenge with cancer treatment, including oral anticancer drugs. A review of claims data showed that a majority of publically funded oral anticancer drugs were filled in the community where pharmacists may not necessarily possess the specialized knowledge, skills, and experience required to provide effective patient care. A survey of community pharmacists in Ontario was conducted to identify the behaviours and preferences of community pharmacists specific to the management of treatment-related toxicities in order to standardize cancer care in this area. Methods: An electronic questionnaire was distributed to approximately 5000 community pharmacists. The 21-question survey gathered information on the demographic profile of the pharmacists, basic geographic and socioeconomic variables associated with their practice setting, current toxicity management practices, education and training needs, and preferences for communicating with other providers. Results: Of 349 pharmacists, almost all (94.9%) were interested in managing chemotherapy-related toxicities as part of their work, but the majority (77.1%) did not feel that their current level of pharmacy training has provided them with an oncology education sufficient for the demands of their practice. Approximately 52% of respondents indicated that they have reached out to the health care provider at a cancer centre, and of those, 72.7% reported that their questions were resolved within 48 h. More than half of all survey respondents (53.9%) indicated that they would prefer to receive a response within 12 h from cancer centres. Conclusions: The results of this study support the need to provide community pharmacists with oncology-specific training and timely correspondences from providers at prescribing institutions in order to manage toxicities.

show abstract

Section: Resultssupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Managing chemotherapy-related toxicities in the community setting: A survey of pharmacists in Ontario

Pardhan

Lakhani

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…Definitions Although polypharmacy has been defined in a number of ways, 7,12,14,23) we defined it here as the regular use of six or more medications according to "Total Drug Evaluation and Management Healthcare Reimbursement Fee," the Japanese Medical Service Fee system. In this system, pharmacists are eligible to receive a healthcare reimbursement fee from Japan's National Health Insurance system when they eliminate two or more drugs from a patient's prescription of six or more regular medications, as prescribed through the Japanese National Healthcare system.…”

Section: Study Design and Data Sourcementioning

confidence: 99%

A Nationwide Survey of Community Pharmacist Contributions to Polypharmacy in Opioid-Using and Non-using Cancer Patients in Japan

Suzuki

Uchida

Suga

et al. 2019

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

No nationwide study on polypharmacy in palliative care among Japanese community pharmacies has yet been conducted. We conducted an online questionnaire survey for community pharmacist members of The Japanese Society for Pharmaceutical Palliative Care and Sciences regarding their contributions to cancer patients who regularly used six or more drugs, including opioids, in service during the two-month period from October to November 2017. Of 579 community pharmacists, 83 responded to the survey (14.3%). Among them, 47.0 and 27.7% of respondents replied that more than 40% of opioid-using and non-using cancer patients were prescribed six or more regular medications, respectively. The proportion of patients with polypharmacy was marginally higher among opioid-using than non-using patients. Additionally, 31.3 and 22.9% of respondents replied that a low or moderate rate of opioid-using and non-using patients with polypharmacy received inappropriate prescriptions, respectively, including "unnecessary medications," "adverse drug reactions" and "duplication of pharmacological effect." The proportion of patients who received inappropriate prescriptions was significantly higher among opioid-using than non-using patients. Furthermore, 37.3 and 19.3% of respondents replied that pharmacist's recommendations contributed to drug reduction in opioidusing and non-using patients with polypharmacy who received inappropriate prescriptions, respectively. The responders with higher confidence in palliative care showed more success rate for reducing inappropriate medications. Our findings suggest that opioid use can be associated with an increased risk of polypharmacy in cancer patients, and that recommendations by a population of community pharmacists can reduce inappropriate medications and improve adverse drug reactions in both opioid-using and non-using cancer patients with polypharmacy.

show abstract

Patients sous anticancéreux : pratiques et attentes des pharmaciens officinaux

Macé,

Boulin,

Cransac

et al. 2024

Bulletin du Cancer

View full text Add to dashboard Cite

Evaluation of community pharmacist ability to ensure the safe use of oral anticancer agents: a nationwide survey in Japan

Cited by 25 publications

References 17 publications

Managing chemotherapy-related toxicities in the community setting: A survey of pharmacists in Ontario

Managing chemotherapy-related toxicities in the community setting: A survey of pharmacists in Ontario

A Nationwide Survey of Community Pharmacist Contributions to Polypharmacy in Opioid-Using and Non-using Cancer Patients in Japan

Patients sous anticancéreux : pratiques et attentes des pharmaciens officinaux

Contact Info

Product

Resources

About